Psychedelic Research and Access in
Mauritius
Mauritius is currently a low-signal country page in Blossom. Blossom does not currently link this page to psychedelic clinical trials, stakeholders, or events, so it should be read as a database placeholder rather than a mature research profile.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inMauritius.
- 1
Blossom currently tracks no country-linked psychedelic clinical trials for Mauritius.
- 2
Blossom currently tracks no linked psychedelic stakeholders or events for Mauritius.
- 3
No verified country-specific psychedelic access pathway is recorded in this lightweight page content.
- 4
Future updates should prioritise verified trial registrations, regulator or health-ministry sources, and locally based organisations before adding more detailed claims.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Mauritius, but the page does include 1 stakeholder.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 1
- Events
- 0
None marked active
No linked trials
Linked organisations
No linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Mauritius maintains stringent controls on classical psychedelic compounds: most serotonergic psychedelics (psilocybin/psilocin, DMT, mescaline, MDMA, 5-MeO-DMT, 2C-X, etc.) are listed in the national Dangerous Drugs Act schedules and are prohibited outside very narrow authorised medical, forensic or research exceptions. Ketamine is controlled but remains an authorised medicinal anaesthetic subject to strict regulatory controls and prescription limits; newer commercial esketamine (Spravato) does not appear on public registration lists and is not a...
Regulatory Status
No country-specific psychedelic access review has been completed for Mauritius. Readers should not infer legal medical availability, reimbursement, or private clinical access from this placeholder; any access question should be checked compound by compound against current local law and medicines regulation.
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Strictly IllegalMedical Access
Mauritius maintains stringent controls on classical psychedelic compounds: most serotonergic psychedelics (psilocybin/psilocin, DMT, mescaline, MDMA, 5-MeO-DMT, 2C-X, etc.) are listed in the national Dangerous Drugs Act schedules and are prohibited outside very narrow authorised medical, forensic or...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Mauritius.
Open scorecard →Psychedelic Stakeholders in Mauritius
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Mauritius.